Aier Ophthalmology was founded in 2002, with a medical network covering Asia, Europe, and North America. It was listed in Shenzhen, China in 2009 (stock code: 300015); The company's branches in Europe and Southeast Asia are listed in Madrid, Spain (CBAV. MC) and Singapore (SGX: 40T), respectively. As of July 31, 2025, there are a total of 976 Aier Eye brand hospitals, eye centers, and clinics worldwide. Among them, there are 807 eye clinics in mainland China, 9 in Hong Kong, and more than 160 eye clinics overseas, including 1 in the United States, 141 in Europe, and 18 in Southeast Asia.

As a global ophthalmic medical group, Aier Ophthalmology currently adheres to the strategic policy of domestic medical development as the main line, domestic and international dual track development, and common progress. It introduces and absorbs internationally synchronized ophthalmic technology and medical management concepts, and promotes the development of China's ophthalmic industry with a professional, large-scale, and scientific model, striving to improve the overall level of China's ophthalmic medical care and radiate globally. Through continuous practice and the introduction and absorption of international advanced medical management experience, Aier Eye Hospital has successfully explored a set of eye hospital chain operation and management models that are suitable for China's national conditions and market environment - "graded chain", promoting the efficient use of core medical resources, effectively connecting with the national medical reform policy of "graded diagnosis and treatment, two-way referral", and truly enabling the people to enjoy high-quality and accessible medical resources.

Scientific research and innovation, as well as talent cultivation, are the cornerstone of long-term development. Aier Ophthalmology continuously increases its research investment, vigorously supports the development of cutting-edge and original ophthalmic academic research, and fully promotes the eye health ecosystem strategy on a global platform. Since the establishment of the Aier College of Ophthalmology at Central South University in 2013, Aier Ophthalmology has successively promoted strategic cooperation with many well-known domestic and foreign universities, fully leveraging the unique advantages of enterprises and universities, and conducting in-depth cooperation in hospital co construction, talent cultivation, faculty team building, teaching and research, jointly building a top ophthalmic medical research platform, cultivating more outstanding ophthalmic medical talents for society, and truly contributing wisdom and strength to the innovative development of Chinese ophthalmology and visual science.

On this basis, Aier Ophthalmology continues to build a three-dimensional scientific research platform, and has so far established an innovative integrated platform of science, education, and research with "eight institutes, two stations, two bases, and three centers" nationwide. Eight institutes: Aier Institute of Ophthalmology, Aier Institute of Optometry, Aier Institute of Corneal Disease, Aier Institute of Refraction, Aier Institute of Retina, Aier Institute of Glaucoma, Aier Institute of Cataract and Artificial Lens, Wuhan Aier Institute of Ophthalmology. Approved to establish "two stations": National Postdoctoral Research Workstation and Academician Expert Workstation; Second Base ": International Science and Technology Cooperation Base for Optometry, and Work Base for the" Hai Zhi Plan "; Three Centers: Eye and Vision Engineering Technology Research Center, Clinical Medical Research Center for Ocular Surface Diseases, and Enterprise Technology Center; Jointly establish innovative platforms such as the "AIER Ophthalmology Institute of Chinese Academy of Sciences Digital Ophthalmology Joint Laboratory".

On the occasion of its ten-year listing, Aier Ophthalmology has put forward three strategic goals guided by the principle of "innovation driven, technology driven". One is to cover the ophthalmic medical service network in China's vast urban and rural counties, so that ordinary people can enjoy high-quality and accessible ophthalmic medical services at their doorstep, and promote the Healthy China strategy. The second is to build world-class and national level ophthalmic medical centers, effectively improve China's ophthalmic medical technology level, and catch up with the world's advanced level. The third is to promote the progress of human ophthalmology and visual science through global layout and comprehensive coordinated development of medicine, education, research, production, and investment.

Over the course of 20 years of entrepreneurial development, Aier Ophthalmology has gathered and cultivated a team of experienced and innovative management personnel, as well as a team of highly skilled and rigorous ophthalmologists and doctors. As of now, Aier Eye Hospital Group and its subsidiaries have a total of over 50000 employees worldwide, including more than 7100 ophthalmologists and optometrists (including overseas), including a large number of doctoral supervisors, master's supervisors, doctoral and postdoctoral fellows, scholars studying in Europe and America, and core experts with rich clinical experience.

The development and growth of Aier Ophthalmology has always been based on the original intention of "dedicating love to human eye health", with the mission of "enabling everyone, regardless of poverty or wealth, to enjoy the right to eye health", adhering to the principle of "patient-centered", and pursuing the harmonious unity of social responsibility and self-development. Through the pioneering "cross subsidy" model, while providing patients with higher quality ophthalmic medical services, we comprehensively carry out blindness prevention and treatment work, participate in social welfare, help vulnerable groups, actively unite forces from all walks of society, and promote the comprehensive development of China's blindness prevention and even national eye health. In 2018 and 2020, it won the 10th and 11th highest charity award of the Chinese government, the "China Charity Award", as well as honors such as the "China Public Welfare Enterprise Award", "Best Social Responsibility Listed Company", and "Hunan Charity Award" at the China Public Welfare Annual Conference. At the same time, actively responding to the call of the state, as a representative enterprise of China, we took the lead in participating in public welfare activities such as the "Bright the Belt and Road Initiative" and the "Bright Mekong Initiative", which was highly praised by the organizers, the governments of recipient countries and patients, and gradually developed into a famous film of global charity activities.

Aier Ophthalmology has been rated as one of the "Top Ten Most Respected Listed Companies in China" by authoritative institutions for several consecutive years, and has won the "Huapu Award" at the China Brand Festival. It has also been honored with multiple awards such as the "Best Continuous Investment Value Award", "Best Shareholder Return Award for Chinese Listed Companies", and "Industrial Contribution Award for Chinese Listed Companies". It has successfully been selected as a constituent stock of the Shanghai and Shenzhen 300 Index and the MSCI China Index.